Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota. Show more
Location: 16305 36th Avenue North, Minneapolis, MN, 55446, United States | Website: https://www.celcuity.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
516.1M
52 Wk Range
$7.58 - $19.77
Previous Close
$13.62
Open
$13.57
Volume
171,554
Day Range
$13.35 - $13.94
Enterprise Value
398.5M
Cash
205.7M
Avg Qtr Burn
-25.56M
Insider Ownership
13.21%
Institutional Own.
82.08%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Gedatolisib + trastuzumab-pkrb Details HER2+ Metastatic Breast Cancer (mBC) | Phase 2 Update | |
Gedatolisib + darolutamide (Nubeqa®) Details Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 Update |